Doug Engfer Joins Medrio’s Board of Directors

Share Article

Appointment of Engfer Follows Release of Medrio’s New Product Suite

Medrio, a provider of advanced eClinical software as a service (SaaS) for clinical research, today announced it has appointed Doug Engfer to its Board of Directors. Doug Engfer, Founder and CEO of invivodata, brings more than 25 years of expertise to Medrio.

“We are excited to welcome Doug to the board,“ said Mike Novotny, Founder and CEO of Medrio. “With his deep understanding of clinical research and technology, he is the perfect addition to further Medrio’s growth while helping us to continue to provide exceptional service to our customers.”

An entrepreneur from a long line of entrepreneurs, Doug Engfer has more than 25 years of executive leadership experience, focused on building productive organizations that expand their customers' top-line revenue. Most recently, Doug co-founded invivodata (now part of ERT), serving as President, CEO, and Board Chair. Invivodata permanently changed pharmaceutical clinical research by pioneering the direct collection of valid, reliable patient self-report data. Before that, Doug founded The Windward Group (now part of Microsoft), a Silicon Valley software development services firm. Notable Windward successes include the Palm® connected organizer, FedEx® Ship™ desktop shipping software and Apple's QuickTime® multimedia software. Prior to his service with Windward, Doug worked at CWA, Wyse Technology, GRiD Systems and Control Data Corporation.

About Medrio
Medrio offers an integrated eClinical Software as a Service (SaaS) platform with a fully hosted Electronic Data Capture (EDC) system that drastically reduces study timelines and costs by putting study managers in control of their studies. By enabling studies to be built completely online without the need for any custom development, Medrio eClinical software allows studies to be ready in days instead of weeks. Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by a number of leading contract research organizations (CROs), as well as biopharmaceutical and device companies. Founded in 2005, Medrio is headquartered in the San Francisco Bay Area.

For more information visit: http://www.medrio.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Moir
Medrio
+1 4152769263
Email >
@medrio
Follow >
Visit website